The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) met its primary endpoint in the DELIVER phase III trial by significantly lowering the risk of cardiovascular death or ...

/NOT FOR US MEDIA/ ORLANDO, FL, June 26 /CNW/ - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the ...

Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: ...

The NHS has advised people taking a widely prescribed drug to get urgent medical attention if they develop any of three particular symptoms. These are some of the severe complications associated with ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE) to produce guidance on using dapagliflozin in the NHS in England and Wales. The Appraisal Committee ...

The economic evaluation included within the Bristol-Myers Squibb / AstraZeneca (BMS/AZ) submission to NICE was a patient level simulation. The model was constructed with an Excel spreadsheet front-end ...

NICE has recommended the extension of dapagliflozin as a treatment option for symptomatic chronic heart failure in patients with preserved or mildly reduced ejection fraction. In final draft ...

On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor dapagliflozin has been indicated for ...

PRINCETON, N.J. and LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and AstraZeneca (NYS: AZN) today announced that the European Commission has approved Forxiga ™ (dapagliflozin) ...